Scarica l'app Stockscreener
1.85
0.00%
0.00
Dopo l'orario di chiusura:
1.89
0.04
+2.16%
Precedente Chiudi:
$1.85
Aprire:
$1.82
Volume 24 ore:
6.01M
Relative Volume:
1.53
Capitalizzazione di mercato:
$379.15M
Reddito:
$12.87M
Utile/perdita netta:
$-114.34M
Rapporto P/E:
-0.8079
EPS:
-2.29
Flusso di cassa netto:
$-79.23M
1 W Prestazione:
-10.63%
1M Prestazione:
-7.96%
6M Prestazione:
-32.97%
1 anno Prestazione:
+30.28%
Intervallo 1D:
$1.80
$1.935
Intervallo di 1 settimana:
$1.80
$2.125
Portata 52W:
$1.19
$4.32
Taysha Gene Therapies Inc Stock (TSHA) Company Profile
Nome
Taysha Gene Therapies Inc
Settore
Industria
Telefono
(214) 612-0000
Indirizzo
3000 PEGASUS PARK DRIVE, DALLAS
Confronta TSHA con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
TSHA
Taysha Gene Therapies Inc
|
1.85 | 379.15M | 12.87M | -114.34M | -79.23M | -0.8646 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Taysha Gene Therapies Inc Stock (TSHA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-06-27 | Iniziato | BMO Capital Markets | Outperform |
| 2024-04-09 | Iniziato | Piper Sandler | Overweight |
| 2023-02-01 | Downgrade | Jefferies | Buy → Hold |
| 2023-01-27 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2022-11-09 | Downgrade | Goldman | Buy → Neutral |
| 2022-03-09 | Iniziato | Robert W. Baird | Outperform |
| 2022-03-01 | Iniziato | Wells Fargo | Overweight |
| 2022-02-18 | Iniziato | SMBC Nikko | Outperform |
| 2021-12-16 | Iniziato | Guggenheim | Buy |
| 2021-07-16 | Iniziato | Needham | Buy |
| 2021-06-24 | Iniziato | Truist | Buy |
| 2021-06-15 | Iniziato | BTIG Research | Buy |
| 2021-06-09 | Iniziato | Wedbush | Outperform |
| 2021-06-08 | Iniziato | JMP Securities | Mkt Outperform |
| 2021-05-19 | Iniziato | Cantor Fitzgerald | Overweight |
| 2021-05-11 | Ripresa | Jefferies | Buy |
| 2021-02-24 | Iniziato | William Blair | Outperform |
| 2021-01-05 | Iniziato | Oppenheimer | Outperform |
| 2020-10-19 | Iniziato | Chardan Capital Markets | Buy |
| 2020-10-19 | Iniziato | Goldman | Buy |
| 2020-10-19 | Iniziato | Jefferies | Buy |
| 2020-10-19 | Iniziato | Morgan Stanley | Overweight |
Mostra tutto
Taysha Gene Therapies Inc Borsa (TSHA) Ultime notizie
Wellington Management Group LLP Purchases Shares of 463,192 Taysha Gene Therapies, Inc. (NASDAQ:TSHA) - MarketBeat
Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Shares Purchased by Charles Schwab Investment Management Inc. - Defense World
Taysha Gene Therapies' SWOT analysis: promising rett syndrome stock faces key tests - Investing.com Canada
Thinking about buying stock in Nikola, Delcath Systems, Taysha G - GuruFocus.com
Fmr LLC Has $37.54 Million Stake in Taysha Gene Therapies, Inc. (NASDAQ:TSHA) - MarketBeat
Taysha Gene Therapies (NASDAQ:TSHA) Stock Price Up 6.3%Still a Buy? - MarketBeat
Taysha Gene Therapies announces inducement grant under Nasdaq listing rule - TipRanks
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Taysha Gene Therapies Issues 152,000-Share Stock Option Grant to New Executive Hire - StockTitan
Canadian Imperial Bank of Commerce (CM-N) QuotePress Release - The Globe and Mail
RTW Investments LP Sells 3,853,879 Shares of Taysha Gene Therapies, Inc. (NASDAQ:TSHA) - MarketBeat
Rett Syndrome Market Forecast: Key Drivers and Opportunities - openPR
Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Receives $6.63 Consensus Price Target from Brokerages - MarketBeat
Taysha Gene Therapies (NASDAQ:TSHA) Shares Up 6.3%Time to Buy? - MarketBeat
Acuta Capital Partners LLC Cuts Stake in Taysha Gene Therapies, Inc. (NASDAQ:TSHA) - MarketBeat
TSHA (Taysha Gene Therapies) Dividend Yield % : 0.00% (As of Nov. 26, 2024) - GuruFocus.com
TSHA (Taysha Gene Therapies) EPS without NRI : $-0.29 (TTM As of Sep. 2024) - GuruFocus.com
Realty Income Corp (O-N) QuotePress Release - The Globe and Mail
Taysha Gene Therapies' SWOT analysis: stock poised for growth in Rett syndrome market - Investing.com
TSHA (Taysha Gene Therapies) Days Inventory : 0.00 (As of Sep. 2024) - GuruFocus.com
Amgen (NASDAQ:AMGN) vs. Taysha Gene Therapies (NASDAQ:TSHA) Head-To-Head Comparison - Defense World
TSHA (Taysha Gene Therapies) 5-Day RSI : 71.01 (As of Nov. 24, 2024) - GuruFocus.com
Taysha Gene Therapies (NASDAQ:TSHA) Trading Up 13.8%Here's What Happened - MarketBeat
Recent Analysts’ Ratings Updates for Taysha Gene Therapies (TSHA) - Defense World
Canaccord Genuity Group Issues Positive Forecast for Taysha Gene Therapies (NASDAQ:TSHA) Stock Price - Defense World
Taysha Gene Therapies (NASDAQ:TSHA) Stock Price Expected to Rise, Canaccord Genuity Group Analyst Says - MarketBeat
Expert Outlook: Taysha Gene Therapies Through The Eyes Of 7 Analysts - Benzinga
Taysha Gene Therapies Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags - Yahoo Finance
Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Q3 2024 Earnings Call Transcript - Insider Monkey
RA Capital Management, L.P. Increases Stake in Taysha Gene Thera - GuruFocus.com
Taysha Gene Therapies (NASDAQ:TSHA) Shares Gap DownHere's Why - MarketBeat
Hims & Hers stock falls as Amazon launches Telehealth offering - MSN
Avoro Capital Advisors LLC Increases Stake in Taysha Gene Therap - GuruFocus.com
Advance Auto Parts Posts Weak Results, Joins Harrow, Taysha Gene Therapies And Other Big Stocks Moving Lower In Thursday's Pre-Market Session - Benzinga
Creative Planning Makes New $28,000 Investment in Taysha Gene Therapies, Inc. (NASDAQ:TSHA) - Defense World
Hillenbrand Posts Better-Than-Expected Earnings, Joins Beazer Homes, Tapestry, Walt Disney And Other Big Stocks Moving Higher On ThursdayHuntington Ingalls Indus (NYSE:HII) - Benzinga
Taysha Gene Therapies Inc (TSHA) Q3 2024 Earnings Call Highlight - GuruFocus.com
Taysha Gene Therapies Inc (TSHA) Q3 2024 Earnings Call Highlights: Clinical Progress and ... - Yahoo Finance
Taysha Gene Therapies Advances in Rett Syndrome Trials - TipRanks
Earnings call: Taysha Gene Therapies reports on TSHA-102 Rett Syndrome trial By Investing.com - Investing.com South Africa
Taysha Gene Therapies, Inc. (TSHA) Reports Q3 Loss, Lags Revenue Estimates - Yahoo Finance
Taysha Gene Therapies Reports Third Quarter 2024 Financial Results and Provides Corporate Update - The Manila Times
Taysha Gene Reports Strong Safety Data, FDA Approval for TSHA-102 Trials; Net Loss Narrows | TSHA Stock News - StockTitan
Taysha Gene Therapies' SWOT analysis: promising Rett syndrome stock faces pivotal year - Investing.com UK
FMR LLC's Strategic Reduction in Taysha Gene Therapies Inc - GuruFocus.com
Neurogene’s Rett Data Draw Optimism Despite Serious Adverse Event - Citeline News & Insights
Preview: Taysha Gene Therapies's Earnings - Benzinga
JMP Securities Reaffirms "Market Outperform" Rating for Taysha Gene Therapies (NASDAQ:TSHA) - MarketBeat
Piper Sandler expects Taysha Gene to recover, maintains $7 shares target - Investing.com UK
U.S. Stock market top gainers: BTC Digital surges by 68.60%, Revance Therapeutics climbed by 20.00% in early trading - Business Upturn
Piper Sandler stays bullish on Taysha Gene shares, maintains Overweight rating - Investing.com UK
Taysha Gene Therapies Inc Azioni (TSHA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.88%
2.65%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):